Ovarian Cancer Clinical Trial
Official title:
Data and Specimen Bank of Patients Diagnosed With, and at High-risk for, Gynecologic Cancers
The purpose of this project is to establish a bank at UVa of tampon samples, cervical swabs, blood, associated tumor specimens that would otherwise be discarded, and relevant medical data from consenting patients that have suspected and/or confirmed gynecological cancer diagnoses. The specimens collected will be saved for analysis on future projects to determine if factors in the specimens are predictive and/or correlated to gynecological cancer diagnoses and/or outcomes
The purpose of this project is to establish a bank at UVa of tampon samples, cervical swabs,
blood, associated tumor specimens that would otherwise be discarded, and relevant medical
data from consenting patients that have suspected and/or confirmed gynecological cancer
diagnoses. The specimens collected will be saved for analysis on future projects to determine
if factors in the specimens are predictive and/or correlated to gynecological cancer
diagnoses and/or outcomes. The bank will contain: 1) 10cc of blood drawn through venipuncture
annually; 2) tampons placed in the patients vagina prior to surgery or clinic visit; 3) swabs
of the endocervical canal; 4) freshly collected leftover and to-be-discarded tumors from
ovarian, uterine, cervical, as well as leftover normal tissue, and ascites fluid, from
samples collected for diagnostic purposes. These samples and patient-associated medical
record data will be banked and used for future research and analyses. Samples will be saved
in multiple formats for later tumor profiling (i.e. FFPE, snap frozen, in RNA-later, etc).
These samples and information will be used to determine the underlying causes of cancers and
chemoresistance, so that better methods of treatment, management, and prevention of
gynecological cancers may be discovered in the future.
Samples will be linked and coded, with all HIPAA protected information removed, for storage
and sharing with other investigators to protect patient information. Only coded samples and
clinical information will be used in this protocol for when samples, information, and/or data
are shared with other investigators at UVa or outside institutions in the future. A separate
password protected/encrypted file will contain the patient identifiers and the key to the
coded sample numbers. This file will only be accessible by the PI or study team listed on
this protocol on UVa premises, and will only be stored on a UVa server behind the UVa
firewall, and will not be stored or accessed on personal computers. Thus, identified patient
information will not be accessible to any individual, except the PI or study team listed on
this protocol, ensuring protection of patient information. In addition, coded patient samples
and medical data from specimens obtained from the University of Alabama-Birmingham, that were
previously collected by the PI under local IRB approval (IRB-HSR #18042), have been
transferred to UVA under a fully executed MTA, and will be assimilated into this databank at
UVa for future research.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |